#14TH QUARTER 2021 EARNINGS PRESENTATION FEBRUARY 22, 2022 ♡ BEAUTYHEALTH™#2DISCLAIMER This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), the calculation of certain key financial and operating metrics, capital expenditures, the introduction of new products, expansion into new markets and the ability to execute certain strategic initiatives. Some of the forward-looking statements can be identified by the use of forward-looking words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. These are intended to identify forward- looking statements. All forward-looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this Presentation, and may include, without limitation, changes in general economic conditions as a result of COVID-19, all of which are subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation constitute the Company's judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this Presentation are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions we believe to be reasonable, there is no assurance that the expected results will be achieved. Many factors could adversely affect our business and financial performance. We discussed a number of material risks in our Prospectus filed pursuant to Rule 424(b)(5) of the Securities Act on July 26, 2021 and other filings with the Securities and Exchange Commission. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise. Description of Non-GAAP Financial Measures In addition to results determined in accordance with accounting principles generally accepted in the United States of America (GAAP), management utilizes certain non-GAAP financial measures such as adjusted gross margin, adjusted EBITDA, and adjusted EBITDA margin for purposes of evaluating ongoing operations and for internal planning and forecasting purposes. We believe these non-GAAP financial measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to non-recurring, unusual items. Management uses adjusted gross margin to measure profitability and the ability to scale and leverage the costs of Delivery Systems and Consumables. The continued growth of Delivery Systems is expected improve adjusted gross margin, as additional Delivery Systems sold will increase our recurring Consumables net sales, which has higher margins. Management believes adjusted gross profit and adjusted gross margin are useful measures to the Company and its investors to assist in evaluating operating performance because they provide consistency and direct comparability with past financial performance and between fiscal periods, as the metrics eliminate the effects of amortization and depreciation, which are non-cash expenses that may fluctuate for reasons unrelated to overall continuing operating performance. Adjusted gross margin has been and will continue to be impacted by a variety of factors, including the product mix, geographic mix, direct vs. indirect mix, the average selling price on Delivery Systems, and new product launches. Management expects adjusted gross margin to fluctuate over time depending on the factors described above. Management uses adjusted EBITDA and adjusted EBITDA margin to facilitate internal comparisons of historical operating performance on a more consistent basis and uses these measures for business planning purposes. Management also believes this information will be useful for investors to facilitate comparisons of operating performance and better identify trends in the business. Management expects adjusted EBITDA margin to increase over the long-term, as the Company continues to scale and achieve greater operating leverage. The Company calculates adjusted EBITDA as net income (loss) adjusted to exclude: change in fair value of public and private placement warrants, change in fair value of earn-out shares liability, other expense, net; interest expense; income tax benefit (expense); depreciation and amortization expense; stock-based compensation expense; foreign currency (gain) loss; management fees incurred from historical private equity owners; one-time or non-recurring items such as transaction costs (including transactions costs with respect to the Business Combination); and restructuring costs (including those associated with COVID-19). 2#31 Opening Remarks 2 4th Quarter 2021 & Fiscal Year 2021 Financial Results 3 2022 Outlook 4 Q&A Beauty Health Participants AGENDA BRENT SAUNDERS Executive Chairman ANDREW STANLEICK President and Chief Executive Officer 3 LIYUAN WOO Chief Financial Officer#4DERMA GLYSAL PREP BRITEN 882434 HYDRA OPENING REMARKS BRENT SAUNDERS Executive Chairman ANDREW STANLEICK President and Chief Executive Officer#51 2 3 4 5 SIGNIFICANT NET SALES GROWTH DEMONSTRATES STRENGTH OF BRAND $260.1 mm exceeded 2021 guidance with a +118.3% increase vs FY20 and +56.2% increase vs FY19 I KEY HIGHLIGHTS 4Q21 GROSS MARGIN / ADJUSTED GROSS MARGIN¹ EXPANSION OF +1,210 BPS / +870 BPS VS 4Q20 72.9% GAAP / 76.5% adjusted as cost leverage increasing with growth and distributor acquisition accretion offset supply chain environment CONTINUED EXECUTION OF EXISTING STRATEGY Master Plan remains in place, focus on flawless execution and expanding talent GROWTH OPPORTUNITY REMAINS SIGNIFICANT 2022 outlook of double-digit sales growth via innovation and geographic expansion I VISIBILITY INTO ACCELERATED PATHWAY TO GREATER PROFITABILITY Final elevated investment year of 2022 paves way for adjusted EBITDA margin¹ expansion in 2023 Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure 5#6THE MASTER PLAN We are a category creator. We deliver beauty health experiences - reinventing our consumer's relationship with their skin, their bodies, and their self-confidence. ∞ Expand our footprint by selling innovative products and connected experiences to providers and consumers. Invest in our providers, especially the trusted a/esthetician, turning them into brand evangelists and advocates providing first-class experiences Nurture direct relationships with our consumers, building brand awareness and driving them to our trusted community Build our global infrastructure and a connected technology platform to fuel growth and community engagement Supercharge our platform with targeted acquisitions to complement our portfolio and spin our flywheel faster#7RPOSE we make in the world. ople to face life face first. draFacial Nation 33 hydrafacal VALUES How we behave and make decisions We expect to win-we hire winners Open company, no BS No drama, no divas, no meanies. Il The Customer is #1, REALLY! Execution is experted Act urgently, thi Make the little he big thi THE HYDRAFACIAL BRAND VISION Ong Brah speiros VE WORK & PLAY 1 BEAUTY IS A FEELING) O dola VOICE 海菲秀 Westsiegh Watery pr hydrafacial NO PAIN ALL GAIN ① 海作機 EXPRESSION T FACE LIFE 闪耀而至 FACE FIR ! FACE FACE butchel rataral CHART BEAUTY IS A FEELING) BER 【等你来秀 海菲秀 LIVE WORK PLAY NO PAIN ALL GAIN ( 海洋秀 13 P 4TH QUARTER / FY 2021 RESULTS & 2022 OUTLOOK LIYUAN WOO Chief Financial Officer#8Provider delivers HydraFacial experience to consumer 2 Consumables purchased by provider BRIGHTEN ACTIV-4 BETA-HD 1 Delivery System sold to provider THE HYDRAFACIAL ECONOMIC MODEL ANTIOX-F I First-time buyers Existing providers buying additional Delivery Systems Existing providers upgrading older Delivery Systems 1 Provider purchases a Delivery System, empowering them to offer HydraFacial experiences to their consumers 2 Each HydraFacial experience requires the use of consumables (tips, solutions, serums) These consumables are sold exclusively by Beauty Health to our providers ■ 3 Provider markets HydraFacial experiences to their consumers. 8 ■ ■ BeautyHealth drives additional consumer awareness with marketing activation, pushing incremental demand to our providers Consumers re-visit for recurring HydraFacial experiences (our superconsumers visit 8x / year) Provider recognizes high ROI realized by offering HydraFacial experiences, leading to additional Delivery System purchases Glossary of Key Performance Indicators Delivery System ASP: Average sale price for a Delivery System Delivery Systems Sold: Number of Delivery Systems sold during a period Install Base: Total number of Delivery Systems actively employed by providers to offer experiences to consumers#9Net Sales ($mm) $49.9 7.3 8.4 4Q19 13,872 Install Base 60.8% 34.2 Gross Margin 4Q20 72.9% 4Q21 Americas EMEA APAC $37.9 6.8 26.9 4TH QUARTER 2021 FINANCIAL HIGHLIGHTS 4Q20 +105.6% YoY 67.8% 4Q21 vs 4Q19 growth +56.0% +64.1% +84.2% $77.9 12.0 15.5 50.4 4Q2 20,399 Install Base +47.5% 76.5% +870bps since 4Q20 4Q20 4Q21 Adjusted Gross Margin³ GAAP Gross Margin vs the comparable quarter in 2019 2 vs 4Q19 as 4Q20 was heavily impacted by COVID 3 Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure Net Sales Growth 36.9% 1Q21 57.1% 2Q21 3Q21 YOY Sales Growth 71.9% $7.0 14.8% Adjusted EBITDA ($mm)³ 1Q21 56.0% 4Q21 $11.4 17.1% 2Q21 -% margin (4.8%) 2 1Q21 $5.8 8.5% 3Q21 39.9% 2.5% 2Q21 3Q21 4Q21 Sequential Sales Growth $8.5 10.9% 14.3% 4Q21#10($mm) Gross Profit Selling & Marketing G&A R&D Net Sales ($mm) $37.9 4Q20 4Q21 $56.8 37.0 25.0 1.9 4Q20 $23.0 15.9 11.0 0.9 $77.9 4Q21 4TH QUARTER COST DETAIL Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure Change +$33.8 +21.1 +14.0 +1.0 % Sales 4Q21 72.9% 47.6% 32.2% 2.4% 10 4Q20 60.8% 42.0% 29.0% 2.3% Change Commentary +12.1% +5.6% +3.1% +0.1% $3.6 9.4% H 4Q20 ■ Increase driven by higher sales volumes, fixed cost leverage, and distributor acquisition accretion, partially offset by higher logistics costs Higher investment in marketing and increased sales commissions due to increase in sales Increased spend on developing infrastructure for global expansion, as well as one-time costs Adjusted EBITDA ($mm)¹ Continued investment in innovative products and services -% margin $8.5 10.9% 4Q21#11December 31, 2021 (unless otherwise stated) Cash and Cash Equivalents Warrants Convertible Debt Revolving Credit Facility Shares Outstanding I Inclusive of the net proceeds of the convertible notes 2 As of 02/18/22 I BALANCE SHEET HIGHLIGHTS $901.9 million cash and cash equivalents on balance sheet¹ 100% of Public Warrants exercised or redeemed by 11/05/21 Approximately 7 million Private Warrants outstanding $750 million 1.25% convertible notes due 2026 Use of proceeds: capped call transaction, potential future acquisitions, working capital expenditures, and general corporate purposes Conversion price of $31.76; capped call agreement provides dilution protection up to $47.94 $50 million Senior Secured Credit Facility borrowed by Edge Systems LLC (HydraFacial US operating entity); undrawn Use of proceeds: working capital, general corporate purposes Allows flexibility for future M&A; ex-US operations unencumbered; convertible debt excluded from covenants 25-35bps undrawn commitment fee Weighted average shares outstanding of 146.3 million in Q4 2021 Approximately 150 million current shares outstanding2 Ample liquidity to pursue disciplined M&A and invest in the Beauty Health community 11#12Net Sales ($mm) $166.6 15.8 28.4 122.4 2019 Americas EMEA APAC $119.1 14.5 23.2 81.5 2020 +118.3% YoY 7 Direct markets entered FY21 vs FY19 growth $260.1 +56.2% 43.7 +176.6% 47.0 +65.2% 169.4 +38.4% 2021 56.2% Net Sales Growth vs 2019 FISCAL YEAR 2021 HIGHLIGHTS Gross Margin 56.4% Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure 69.9% 2020 2021 GAAP Gross Margin +$892.4mm Cash to balance sheet 6,191 Delivery Systems Sold 12 65.5% 74.0% 2021 2020 Adjusted Gross Margin¹ Global ERP Phase 1 implemented $22,080 Delivery System ASP Adjusted EBITDA ($mm)¹ $7.7 6.5% 2020 -% margin $32.7 12.6% 2021 10 Research analysts covering SKIN 20,399 Install Base#13Net Sales ($mm) 23% -27% 2022E Net Sales Growth $166.6 2019 $119.1 2020 Capital Expenditures Outlook Up to $20.0mm $260.1 2021 $320.0 - $330.0 2022E Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure 2022 OUTLOOK Adjusted EBITDA ($mm)¹ Final elevated investment year Return to EBITDA focus in 2023 $7.7 2020 13 $32.7 2021 ~$50.0 2022E 2022 Growth Initiatives mm Increase Innovation Deepen and expand engagement Invest in Providers Convert them into brand evangelists Expand Awareness Drive consumer demand Go Global Build infrastructure to support worldwide growth Pursue M&A Expand our portfolio#14BRENT SAUNDERS Executive Chairman Q&A ANDREW STANLEICK President and Chief Executive Officer 14 LIYUAN WOO Chief Financial Officer#15drafacial hydrafacial BEAUTY IS A FEELING Wifi Las Gint LOVED AROUND THE WORLD AND NEAR YOU face life face first ESTIC APPENDIX#16RECONCILIATION OF NON-GAAP MEASURES Reconciliation of Gross Profit to Adjusted Gross Profit ($mm) Net sales Less: cost of sales Gross profit Gross margin Adjusted to exclude the following: Stock-based compensation expense Depreciation and amortization expense Adjusted gross profit Adjusted gross margin Three Months Ended December 31, 2021 $77.9 ($21.1) $56.8 72.9% 0.2 2.7 $59.6 76.5% 2020 $37.9 ($14.8) $23.0 60.8% 2.6 $25.7 67.8% 16 Year Ended December 31, 2021 $260.1 ($78.3) $181.8 69.9% 0.4 10.3 $192.5 74.0% 2020 $119.1 ($51.9) $67.2 56.4% 10.8 $78.0 65.5%#17Reconciliation of Net Income (Loss) to Adjusted EBITDA and Adjusted EBITDA Margin Three Months Ended 06/30/21 $66.5 (139.4) ($mm) Net sales Net income (loss) Adjusted to exclude the following: Change in fair value of warrant liability Change in fair value of earn-out shares liability Depreciation & amortization expense Stock-based compensation expense RECONCILIATION OF NON-GAAP MEASURES (CONT'D) Interest expense Income tax benefit Foreign currency loss, net Other expense (income) Management fees Transaction related costs² 12/31/20 $37.9 (7.5) 3.5 5.8 (3.0) 0.1 0.5 3.2 1.0 $3.6 9.4% 03/31/21 $47.5 (3.3) 3.6 0.0 5.7 (0.3) 0.3 0.1 0.7 0.1 $7.0 14.8% 72.0 36.5 3.7 3.5 2.1 (1.9) 4.3 0.1 30.4 0.1 $11.4 17.1% 09/30/21 $68.1 (215.1) 199.3 10.6 4.6 5.1 0.5 (1.1) 0.4 (0.0) 1.2 0.5 $5.8 8.5% 17 12/31/21 $77.9 (17.3) 6.0 6.0 3.8 3.5 1.1 (0.6) 0.2 2.6 3.3 $8.5 10.9% Year Ended December 31, 2020 $119.1 (29.2) 14.5 0.4 21.3 (9.3) 0.0 1.5 4.2 4.3 $7.7 6.5% 2021 $260.1 (375.1) 277.3 47.1 17.8 12.4 11.8 (2.2) 0.1 4.5 0.2 34.9 4.0 $32.7 12.6% Other non-recurring and one-time fees³ Adjusted EBITDA Adjusted EBITDA margin 1 Represents quarterly management fees paid to the former majority shareholder of the Company based on a pre-determined formula. Following the Business Combination, these fees are no longer paid. 2 For the year ended December 31, 2021, such amounts primarily represent direct costs incurred with the Business Combination, including $21.0 million paid to the former owner of HydraFacial, and to prepare HydraFacial to be marketed for sale by HydraFacial's shareholders in previous periods. 3 For the three months ended and year ended December 31, 2021, such costs primarily represent one-time retention awards related to the distributor acquisitions and executive recruiting and severance fees. For the three months ended and year ended December 31, 2020, such costs primarily represent COVID-19 related restructuring cost of $0.8 million and $3.2 million, respectively, including write-off of expired Consumables, discontinued product lines, human capital and cash management consultants and, to a lesser extent, costs associated with a former warehouse and assembly facility during the transition period.#18♡ BEAUTYHEALTH WE ARE A CATEGORY CREATOR... DEMONSTRATING EXCITING GROWTH... USING A PROFITABLE & SCALABLE BUSINESS MODEL... TM IN A MARKET WITH HUGE GLOBAL OPPORTUNITY.